Cancer & Disease Research
COVID-19 protects unvaccinated from reinfection
Unvaccinated people who have a previous COVID-19 infection have a level of protection from future infections that's comparable to protection provided by mRNA vaccines, according to a new study published on April 20 in JAMA Network Open. Read More
Video from AACR 2022: Does the microbiome predict precervical cancer risk?
NEW ORLEANS - Does the microbiome provide clues to the precervical cancer risk of women? This is the question that Katherine Tossas, PhD, is investigating. She shared her thoughts on this topic and on reproductive justice in a video interview at the American Association for Cancer Research (AACR) annual meeting. Read More
COVID data repository helps track pandemic in SF hospitals
ORLANDO -- Consistent persistence in the face of chaos is how San Francisco Department of Public Health Chief Information Officer Eric Raffin and his team implemented their COVID-19 hospitalization data repository. Raffin shared his experience during a Tuesday session at the 2022 Healthcare Information and Management Systems Society meeting. Read More
Focus on drug-manufacturing optimization prioritizes patient health
As medical innovations and therapeutics advance rapidly and dramatically increase in scale, there is a critical need for manufacturing processes that can keep up with this pace. This often calls for updates, overhauls, and collaboration among companies to maintain such a high standard of production. Read More
Colonic gene mapping provides insights into intestinal diseases
Researchers have used spatial transcriptomics to uncover an unprecedented view of the molecular regionalization of the murine colon. This research, published in Nature Communications on February 11, provides novel insights into inflammatory bowel disease. Read More
mRNA-based therapeutics pioneer innovation in the biopharmaceutical industry
In the age of COVID-19, many novel therapeutics have been brought to the forefront, most notably mRNA-based therapies. This technology has been used in two of the most prominent COVID-19 vaccines currently available in the U.S. under the U.S. Food and Drug Administration emergency use authorization. As a result, some companies are expanding mRNA-based technology to apply it to other therapies while further strengthening its use in vaccines. Read More
CAR T-cell therapy collaborations expand cancer treatment options
Considering the broad range of the causes of cancer and the heavy impact on patients, advanced and innovative treatments are essential to fighting it. One technology being explored for this purpose is CAR T-cell therapy, because it trains the body's immune system to specifically target cancerous cells, according to Cell and Gene Therapy Business Outlook, a sister publication of ScienceBoard. Some healthcare institutions are collaborating with companies to develop such technologies, including Celularity, Lonza, and the Memorial Sloan Kettering Cancer Center. Read More
Critical step identified in immune system response could lead to new treatments
New research has identified a crucial protein that controls the immune system's release of a key factor in fighting infections. The study, published in the journal Nature Communications on January 10, found that the MNDA protein is necessary for white blood cells to produce a type of interferon. This discovery could lead to new drugs to help fight infections or treat autoimmune conditions. Read More
How COVID-19 has shed light on importance of biotech tools, health equity
As the world enters the third year of the COVID-19 pandemic, it is clear that the virus has taught humanity some very tough lessons, but there have also been significant scientific advances. A panel explored the current challenges facing the industry, along with the silver linings, on January 10 at Biotech Showcase 2022. Read More
FDA authorizes Pfizer's COVID-19 pill
The U.S. Food and Drug Administration (FDA) has issued an emergency use authorization for nirmatrelvir and ritonavir tablets (which are co-packaged for oral use and sold under the brand name Paxlovid) for the treatment of mild to moderate COVID-19 in adults and pediatric patients (age 12 and older) who have tested positive for SARS-CoV-2 and who are at high risk of developing severe COVID-19, including hospitalization or death. Read More
Conferences
International Society for Cell and Gene Therapy Annual Meeting
May 4 - June 7
San Francisco, California United States
Interphex 2022 Conference
May 24-26
New York, New York United States
American Society for Mass Spectrometry Annual Conference
June 5-9
Minneapolis, Minnesota United States
American Society for Microbiology Microbe Meeting
June 9-13
District of Columbia United States
HPLC 2022
June 18-23
San Diego, California United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter